

# Abraxis Patient Access Program (APAP) **Providing Access to Care**

800.564.0216, Press 3

The Abraxis Patient Access Program (APAP) is a program developed to assist insured and uninsured financially needy patients who have been prescribed ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound).

#### **Enrollment is simple.**

### **Step 1: Determine Eligibility**

Contact the Abraxis™ Oncology Resource Center, ARC of Support™, at 800.564.0216 (press 3), Monday through Friday from 8 AM to 8 PM Eastern Time or log on to www.ABRAXANE.com to obtain enrollment forms.

#### **Step 2: Enroll Eligible Patients**

Complete the APAP Enrollment Application and fax to ARC of Support at 866.242.4141. You will need your patient's insurance and financial information to complete the application.

## Visit us at **www.ABRAXANE.com** for additional product and program information.

ABRAXANE for Injectable Suspension is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

**WARNING:** ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available.

ABRAXANE therapy should not be administered to patients with metastatic breast cancer who have baseline neutrophil counts of less than 1,500 cells/mm<sup>3</sup>. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving ABRAXANE.

Note: An albumin form of paclitaxel may substantially affect a drug's functional properties relative to those of drug in solution. DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS.

